All In Biotech

Drug Trial Radar · NCT06533657

Unique Treatment of Oncology Pain in Advanced Cancer

A Phase 2A Study to Investigate the Safety and Preliminary Analgesic Efficacy of Oral Trichomylin® in Male and Female Participants 18 Years of Age and Above With Advanced Cancer and Moderate to Severe Cancer-Related Pain

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

11

Actual

Start

Jun 12, 2025

Primary completion

Apr 15, 2026

Study completion Apr 15, 2026

Sponsor

Lead sponsor
ZYUS Life Sciences Inc.Industry
Sponsor type
Industry
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to severe chronic pain and who are taking a stable dose of long-acting opioid therapy for at least 1 week prior to screening.

Conditions

  • Cancer Pain

Interventions

  • Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)Drug

    Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants That Reach the Stable Dose during Dose TitrationTime frame: Baseline (i.e. Day 1 Dose Titration) and Stable Dose Day 1, up to 14 days
  2. Change in Average Pain Scores from Baseline to Investigational Product DiscontinuationTime frame: Baseline and Investigational Product Discontinuation, up to 23 days
  3. Proportion of Responders to Average Pain from Baseline to Investigational Product DiscontinuationTime frame: Baseline and Investigational Product Discontinuation, up to 23 days
  4. Number of Participants That Reach the Stable Dose during Dose Titration and Respond to Average Pain from Baseline to Investigational Product DiscontinuationTime frame: Baseline and Investigational Product Discontinuation, up to 23 days
  5. Change in Average Pain from Baseline to End of the TitrationTime frame: Baseline and End of Dose Titration, up to 14 days
  6. Change in Pain Interference from Baseline to End of the TitrationTime frame: Baseline and End of DoseTitration, up to 14 days
  7. Change in Pain Interference from Baseline to Investigational Product DiscontinuationTime frame: Baseline and Investigational Product Discontinuation, up to 23 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • CancerCare Manitoba

    Winnipeg, Manitoba, Canada

  • Centre hospitalier de l'Université de Montréal

    Montreal, Quebec, Canada

  • The Research Institute of the McGill University Health Centre

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.